Dr. Fleshner's clinical practice is in urologic oncology with research interests in prostate and bladder cancer.
Neil E Fleshner
Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer.
Urol Oncol. 2018 Feb 14;:
Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis.
Bladder Cancer. 2018 Jan 20;4(1):91-112
Replacing surveillance cystoscopy with urinary biomarkers in followup of patients with non-muscle-invasive bladder cancer: Patients' and urologic oncologists' perspectives.
Can Urol Assoc J. 2018 Feb 06;:
Changing Trends for Suicidal Death in Patients With Bladder Cancer: A 40+ Year Population-level Analysis.
Clin Genitourin Cancer. 2018 Jan 05;:
Total energy expenditure and vigorous-intensity physical activity are associated with reduced odds of reclassification among men on active surveillance.
Prostate Cancer Prostatic Dis. 2017 Dec 14;:
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.
J Clin Oncol. 2017 Dec 13;:JCO2017741173
Defining a cohort of men who may not require repeat prostate biopsy based on PCA3 score and MRI: The dual negative effect.
J Urol. 2017 Nov 23;:
Extended Venous Thromboembolism Prophylaxis After Radical Cystectomy: A Call for Adherence to Current Guidelines.
J Urol. 2017 Nov 04;:
Preventing clinical progression and need for treatment in patients on active surveillance for prostate cancer.
Curr Opin Urol. 2017 Oct 11;:
Lymphadenectomy in Gleason 7 prostate cancer: Adherence to guidelines and effect on clinical outcomes.
Urol Oncol. 2017 Sep 14;:
Martin Barkin Chair, Division of Urology, Department of Surgery, University of Toronto
Professor, Department of Surgery, University of Toronto